VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION

Overview

Journal Retina

Date 2016 Aug 18

PMID 27533774

Citations 9

Authors

Lala Ceklic

Marion R Munk

Ute Wolf-Schnurrbusch

Margarita Gekkieva

Sebastian Wolf

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate visual and morphological outcome in eyes with MRS and choroidal neovascularization (CNV) secondary to pathologic myopia treated with intravitreal (IVT) ranibizumab.

Methods: Post hoc analysis of the patients included in the RADIANCE trial (n = 277) was performed to evaluate the impact of MRS on the functional outcome in patients with myopic choroidal neovascularization (mCNV) undergoing intravitreal ranibizumab injections.

Results: Prevalence of MRS in pathologic myopia population is 6%. Respective patients were generally older than patients without MRS. Study eyes with MRS at baseline (BL) showed an initially poor treatment response after 3 months (mean change in best corrected visual acuity (BCVA) was 2.8 ± 12.4 letters, P = 0.009). After 12 months of treatment however, the mean change in BCVA was 7.1 ± 14.5 early treatment diabetic retinopathy study (ETDRS) letters (P = 0.025). Patients with MRS at baseline received more intravitreal injections than the other RADIANCE patients without MRS (MRS, n = 15 eyes: 5.8 ± 2.1 vs. RADIANCE non-MRS [n = 207 eyes]: 4.0 ± 2.9; P = 0.0001).

Conclusion: Improvement of visual acuity is delayed and reduced after 3 months intravitreal ranibizumab in eyes with MRS and myopic choroidal neovascularization compared to eyes without MRS. More ranibizumab injections are needed in eyes with MRS to gain comparable BCVA at Month 12.

Citing Articles

Key role for inflammation-related signaling in the pathogenesis of myopia based on evidence from proteomics analysis.

Jiang L, Koh J, Seah S, Shan Dan Y, Wang Z, Chan X Sci Rep. 2024; 14(1):23486.

PMID: 39379387 PMC: 11461836. DOI: 10.1038/s41598-024-67337-7.

Progression of macular retinoschisis following intravitreal aflibercept injection for myopic macular neovascularization-a case report and review of literature.

Gopalakrishnan N, Joshi A, Yadav N, Prabhu V, Bavaskar S, Chhablani J BMC Ophthalmol. 2024; 24(1):224.

PMID: 38807066 PMC: 11134714. DOI: 10.1186/s12886-024-03497-4.

Comparison of anatomical and functional outcomes of treating myopic choroidal neovascularization with bevacizumab or ranibizumab.

Woronkowicz M, Hamilton R, Lightman S, Zagora S, Tomkins-Netzer O Int Ophthalmol. 2023; 43(10):3499-3507.

PMID: 37318668 DOI: 10.1007/s10792-023-02755-6.

Vitreoretinal Interface Changes After Anti-vascular Endothelial Growth Factor Treatment in Highly Myopic Eyes: A Real-World Study.

Tsui M, Hsieh Y, Lai T, Hsia Y, Wang S, Ma I Ophthalmol Ther. 2023; 12(3):1693-1710.

PMID: 37004698 PMC: 10164047. DOI: 10.1007/s40123-023-00701-4.

Morphological parameters of myopic choroidal neovascularization as predictive factors of anti-VEGF treatment response.

Castellino N, Battaglia Parodi M, Russo A, Toro M, Fallico M, Bonfiglio V Sci Rep. 2022; 12(1):10435.

PMID: 35729226 PMC: 9213444. DOI: 10.1038/s41598-022-14287-7.

References

Wolf S, Balciuniene V, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T . RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2013; 121(3):682-92.e2. DOI: 10.1016/j.ophtha.2013.10.023. View

Lai T, Luk F, Lee G, Lam D . Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond). 2012; 26(7):1004-11. PMC: 3396182. DOI: 10.1038/eye.2012.97. View

Neelam K, Cheung C, Ohno-Matsui K, Lai T, Wong T . Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012; 31(5):495-525. DOI: 10.1016/j.preteyeres.2012.04.001. View

Paulus Y, Bressler N . Spontaneous improvement in myopic foveoschisis. Eye (Lond). 2014; 28(12):1519-20. PMC: 4268451. DOI: 10.1038/eye.2014.203. View

Folgar F, Jaffe G, Ying G, Maguire M, Toth C . Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014; 121(10):1956-65. PMC: 4515372. DOI: 10.1016/j.ophtha.2014.04.020. View

Takano M, Kishi S . Foveal retinoschisis and retinal detachment in severely myopic eyes with posterior staphyloma. Am J Ophthalmol. 1999; 128(4):472-6. DOI: 10.1016/s0002-9394(99)00186-5. View

Garcia-Ben A, Blanco M, Pineiro A, Mera P, Rodriguez-Alvarez M, Capeans C . Relationship between macular bending and foveoschisis in myopic patients. Optom Vis Sci. 2014; 91(5):497-506. DOI: 10.1097/OPX.0000000000000250. View

Lin L, Shih Y, Hsiao C, Chen C . Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singap. 2004; 33(1):27-33. View

Benhamou N, Massin P, Haouchine B, Erginay A, Gaudric A . Macular retinoschisis in highly myopic eyes. Am J Ophthalmol. 2002; 133(6):794-800. DOI: 10.1016/s0002-9394(02)01394-6. View

10.

Sayanagi K, Ikuno Y, Tano Y . Tractional internal limiting membrane detachment in highly myopic eyes. Am J Ophthalmol. 2006; 142(5):850-2. DOI: 10.1016/j.ajo.2006.05.031. View

11.

Shimada N, Ohno-Matsui K, Baba T, Futagami S, Tokoro T, Mochizuki M . Natural course of macular retinoschisis in highly myopic eyes without macular hole or retinal detachment. Am J Ophthalmol. 2006; 142(3):497-500. DOI: 10.1016/j.ajo.2006.03.048. View

12.

Williams K, Bertelsen G, Cumberland P, Wolfram C, Verhoeven V, Anastasopoulos E . Increasing Prevalence of Myopia in Europe and the Impact of Education. Ophthalmology. 2015; 122(7):1489-97. PMC: 4504030. DOI: 10.1016/j.ophtha.2015.03.018. View

13.

Ciulla T, Cuilla T, Ying G, Maguire M, Martin D, Jaffe G . Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2015; 122(6):1203-11. PMC: 4446183. DOI: 10.1016/j.ophtha.2015.02.031. View

14.

Shimada N, Tanaka Y, Tokoro T, Ohno-Matsui K . Natural course of myopic traction maculopathy and factors associated with progression or resolution. Am J Ophthalmol. 2013; 156(5):948-957.e1. DOI: 10.1016/j.ajo.2013.06.031. View

15.

Veloso C, Kanadani T, Pereira F, Nehemy M . Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2015; 122(8):1569-72. DOI: 10.1016/j.ophtha.2015.04.028. View

16.

Ikuno Y, Sayanagi K, Ohji M, Kamei M, Gomi F, Harino S . Vitrectomy and internal limiting membrane peeling for myopic foveoschisis. Am J Ophthalmol. 2004; 137(4):719-24. DOI: 10.1016/j.ajo.2003.10.019. View

17.

Kang E, Koh H . Effects of Vitreomacular Adhesion on Age-Related Macular Degeneration. J Ophthalmol. 2015; 2015:865083. PMC: 4573628. DOI: 10.1155/2015/865083. View

18.

Rey A, Jurgens I, Maseras X, Carbajal M . Natural course and surgical management of high myopic foveoschisis. Ophthalmologica. 2013; 231(1):45-50. DOI: 10.1159/000355324. View

19.

Parssinen O . The increased prevalence of myopia in Finland. Acta Ophthalmol. 2011; 90(6):497-502. DOI: 10.1111/j.1755-3768.2011.02210.x. View

20.

Jiang C, Wang W, Xu G, Wang L . Retinoschisis at macular area in highly myopic eye by optic coherence tomography. Yan Ke Xue Bao. 2006; 22(3):190-4. View